Role of dopamine agonists in Parkinson's disease therapy
Authors:
- 11 May 2023
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (6) , 863-873
Abstract
Dopamine agonists are an important component of Parkinson's therapy. When weighing up the various therapy options, therapy with levodopa has recently been increasingly preferred due to its stronger efficacy and the ostensibly lower rate of side effects. The advantage of the lower incidence of motor complications during therapy with dopamine agonists was neglected. The occurrence of side effects can be explained by the different receptor affinity to the individual dopaminergic and non-dopaminergic receptors of the individual dopamine agonists. However, the different affinity to individual receptors also explains the different effect on individual Parkinson symptoms and can, therefore, contribute to a targeted use of the different dopamine agonists. Since comparative studies on the differential effect of dopamine agonists have only been conducted for individual substances, empirical knowledge of the differential effect is of great importance. Therefore, the guidelines for the treatment of Parkinson's disease do not consider the differential effect of the dopamine agonists. The historical consideration of dopamine agonists within Parkinson's therapy deserves special attention to be able to classify the current discussion about the significance of dopamine agonists.Keywords
This publication has 108 references indexed in Scilit:
- Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's DiseaseNeurodegenerative Diseases, 2013
- Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trialThe Lancet Neurology, 2013
- Dopamine modulates processing speed in the human mesolimbic systemNeuroImage, 2013
- Human cognitive flexibility depends on dopamine D2 receptor signalingPsychopharmacology, 2011
- Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's diseaseMovement Disorders, 2011
- Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective AntagonistScience, 2010
- Drugs and Valvular Heart DiseaseNew England Journal of Medicine, 2007
- Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor SubtypesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.BMJ, 1993
- Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with LevodopaBMJ, 1971